Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapid Dose TherapeuticsRDTCF 3-Year ROIIC % is 44.53 as of Feb. 2026, which is 11% above its 10-year median of 40.28. The stock has 3 warning signs investors should review. Among 1,322 Biotechnology companies, Rapid Dose Therapeutics ranks better than 71.18% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Rapid Dose Therapeutics's 3-Year ROIIC % for the quarter that ended in Feb. 2026 was 44.53%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Rapid Dose Therapeutics's 3-Year ROIIC % or its related term are showing as below:
RDTCF's 3-Year ROIIC % is ranked better than 71.18% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs RDTCF: 44.53
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Rapid Dose Therapeutics 3-Year ROIIC % Related Terms
Rapid Dose Therapeutics 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDTCF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Rapid Dose Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Dose Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Rapid Dose Therapeutics's 3-Year ROIIC % falls into.
Rapid Dose Therapeutics's 3-Year ROIIC % for the quarter that ended in Feb. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -1.591 (Feb. 2026) - -2.634 (Feb. 2023) )
/
( 4.759 (Feb. 2026) - 2.537 (Feb. 2023) )
=
1.043
/
2.222
=
46.94%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Rapid Dose Therapeutics (RDTCF) has a 3-Year ROIIC % of 44.53 as of Feb. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Rapid Dose Therapeutics and its competitors. This is 11% above median its historical median of 40.28. According to the industry distribution chart, Rapid Dose Therapeutics ranks #381 out of 1322 companies in the Biotechnology industry, placing it in the top 28.8%.
Is Rapid Dose Therapeutics' 3-Year ROIIC % too high?
Rapid Dose Therapeutics' current 3-Year ROIIC % of 44.53 is 11% above median its 10-year median of 40.28. Based on the distribution chart, Rapid Dose Therapeutics ranks #381 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint.
How does Rapid Dose Therapeutics' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rapid Dose Therapeutics ranks #381 out of 1322 companies for 3-Year ROIIC %. This puts Rapid Dose Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Rapid Dose Therapeutics and its competitors. Rapid Dose Therapeutics's current 3-Year ROIIC % is 44.53, which is 11% above median its own 10-year median of 40.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.25, compared to a current price of $0.09 — trading 66% below its estimated fair value. The current 3-Year ROIIC % is 44.53, which is 11% above median its 10-year median of 40.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current 3-Year ROIIC % is 44.53 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDTCF has been successfully added to your 
